This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Index funds can be tax efficient due to low turnover and broad diversification. This intro explains why they often incur fewer taxes and how you can optimize tax outcomes.
23,418 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
A five-foot humanoid robot delivered the game ball at the Brazil vs Norway World Cup clash, signaling a new era for r...
A surprise drop in June inflation is pushing investors to question a July rate hike. Analysts say the july rate hike ...
New research in 2026 argues that the size of your nest egg is less decisive than how much you can safely withdraw eac...
When a TV showdown becomes a real-world rental, fans race to lock in a stay and lenders notice. This article breaks d...
Investors are watching a potential shift at HubSpot as AI features expand across its platform. This guide breaks down...
RBC Capital Markets upgrades Dow Inc. and LyondellBasell to Outperform, citing Iran-related supply squeezes in global...
Capricor's small-cap biotech story hinges on milestones, cash runway, and clinical progress. This guide breaks down w...
A high-stakes Senate hearing over Iran policy put the spotlight on intelligence briefings and political risk. The key...
Federal health officials issued a warning about misleading statements from biotech billionaire Patrick Soon-Shiong re...
As Cerebras moves toward its IPO, investors grapple with hype and reality. This guide breaks down what cerebras ipo: ...
Investors poured into Ripple ETFs at the strongest pace in months, pushing cumulative inflows toward new records. Yet...